株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌の細胞療法市場およびパイプライン概要

Cancer Cell Therapy Market & Pipeline Insight

発行 KuicK Research 商品コード 305976
出版日 ページ情報 英文 195 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌の細胞療法市場およびパイプライン概要 Cancer Cell Therapy Market & Pipeline Insight
出版日: 2014年06月18日 ページ情報: 英文 195 Pages
概要

過去3〜5年で、より複雑な治療法が新たに登場しています。これは従来の医薬品または生物医薬品では治療ができない疾患を治療するために開発された細胞療法です。同市場は、損傷した組織を置換し、体内の修復メカニズムを刺激することによって損傷した組織や臓器を再生させるという有望性をもたらしています。

当レポートでは、癌の細胞療法市場の概要と動向、段階、国、標的別パイプライン概要、前臨床段階における薬剤数、中止・中断された薬剤プロファイルなどをまとめています。

第1章 細胞療法のイントロダクション

  • 細胞療法の起源
  • 細胞療法の構造

第2章 癌治療のイントロダクション

  • 癌治療のための幹細胞移植の種類
  • 樹枝状細胞療法
  • 標的癌治療

第3章 癌の細胞療法市場概要

  • 市場概要
  • 臨床パイプライン概要

第4章 世界市場動向

  • 市場促進因子
  • 市場の課題
  • 将来見通し

第5章 段階、国、標的とする適応別癌の細胞療法治験概要

  • 未知の段階
  • 研究
  • 前臨床
  • 臨床
  • 第1相
  • 第1、2相
  • 第2相
  • 第3相

第6章 上市された癌の細胞療法動向および特許分析

第7章 中断・中止された癌の細胞療法臨床動向

第8章 競合環境

  • Adaptimmune
  • Apceth
  • Argos Therapeutics Inc
  • Celgene Cellular Therapeutics
  • Cellerant Therapeutics
  • Immunicum
  • Innate Pharma
  • Innocell Corporation
  • Kite Pharma
  • Takara Bio

図表

目次

Since the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.

The discovery of cell therapies has changed the notion that cancer was otherwise incurable. With the efficient capability of cell-based therapies, the number of patients being treated successfully of cancer and similar diseases has increased significantly in recent years, thus leading to the increasing popularity of cell therapy across the globe. Cell therapy for cancer treatment thus represents a paradigm shift in healthcare therapies and treatment by focusing on the basic reason of the occurrence of the disease by repairing, replacing or regenerating damaged cells of the body.

With the cell-based therapies growing significantly, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of cancer along with lack of adequate effective treatment is most likely to drive the cancer cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of cancer and other life threatening diseases.

Additionally, cell based therapies, in the next 3-4 year horizon would be increasingly used to have a better and deeper understanding of the working of genetics in the early stages of cell development. This would in turn enable scientists to understand the reasons of abnormal development of cancer cells. Thus, with the complete knowledge of genetic basis for cell development, scientists would be in a better position to develop efficient drugs and prevent the spread of cancer.

“Cancer Cell Therapy Market & Pipeline Insight” Report Highlights & Findings:

  • Cancer Cell Therapy Market Overview
  • Cancer Cell Therapy Market Dynamics
  • Clinical Pipeline by Phase, country & Target Indications
  • Cancer Cell Therapy Drugs in Pipeline: 82
  • Highest Number of Drugs in Preclinical Stage:29
  • Suspended & Discontinued Drug Profiles

Table of Contents

1. Introduction to Cell Therapy

  • 1.1. Origin of Cell Therapy
  • 1.2. Composition of Cell Therapy

2. Introduction to Cancer Therapies

  • 2.1. Types of Stem Cell Transplants for Treating Cancer
  • 2.2. Dendritic Cell Therapy
  • 2.3. Targeted Cancer Therapies

3. Cancer Cell Therapy Market Overview

  • 3.1. Market Overview
  • 3.2. Clinical Pipeline Insight

4. Global Cancer Cell Therapy Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Challenges
  • 4.3. Future Outlook

5. Cancer Cell Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

  • 5.1. Unknown Phase
  • 5.2. Research
  • 5.3. Preclinical
  • 5.4. Clinical
  • 5.5. Phase I
  • 5.6. Phase I/II
  • 5.7. Phase II
  • 5.8. Phase III

6. Marketed Cancer Cell Therapy Clinical Insight & Patent Analysis

7. Suspended & Discontinued Cancer Cell Therapy Clinical Insight

  • 7.1. No Development Reported
  • 7.2. Discontinued
  • 7.3. Suspended

8. Competitive Landscape

  • 8.1. Adaptimmune
  • 8.2. Apceth
  • 8.3. Argos Therapeutics Inc
  • 8.4. Celgene Cellular Therapeutics
  • 8.5. Cellerant Therapeutics
  • 8.6. Immunicum
  • 8.7. Innate Pharma
  • 8.8. Innocell Corporation
  • 8.9. Kite Pharma
  • 8.10. Takara Bio

List of Figures:

  • Figure 1-1: Four Pillars of Global Pharmaceutical Industry
  • Figure 1-2: Composition of Cell Therapy
  • Figure 2-1: Cancer Therapies Overview
  • Figure 3-1: Global Cell Therapy Market (US$ Billion), 2012-2018
  • Figure 3-2: Global Cell Therapy Market by Indications, 2013
  • Figure 3-3: Global Cell Therapy Market by Region (%), 2013 & 2018
  • Figure 3-4: Global Cancer Cell Therapy Market (US$ Billion), 2012-2018
  • Figure 3-5: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 3-6: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 3-7: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 3-8: No Development Reported in Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 3-9: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
  • Figure 3-10: Discontinued Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014
  • Figure 8-1: Adaptimmune Clinical Pipeline Insight
  • Figure 8-2: Apceth Clinical Pipeline Insight
  • Figure 8-3: Argos Therapeutics Clinical Pipeline Insight
  • Figure 8-4: Cellerant Clinical Pipeline Insight
  • Figure 8-5: Immunicum Clinical Pipeline Insight
  • Figure 8-6: Innate Pharma Clinical Pipeline Insight
  • Figure 8-7: Kite Pharma Clinical Pipeline Insight
Back to Top